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The use of pulsed electric fields (PEFs) is a rapidly grow-
ing field with applications in medicine, food, industry, and
environment. This special collection focuses on medical
applications specifically aimed at developing effective can-
cer therapies and understanding the underlying mechanisms
of those approaches. Pulsed electric fields can be applied in
a variety of ways and is typically characterized by the
pulse width (nanosecond to millisecond) and the specific
intended application (ablation, delivery, or diagnostic). A
general term that is used is electroporation, which is a
means to increase the permeability of cells via the use of
PEF and has applications ranging from gene and drug
delivery to ablation to bacterial inactivation to food pro-
cessing. When a cell is exposed to a sufficiently intense
electric field (for a sufficient duration), local defects in the
cell membrane appear and become permeable to molecules
that otherwise cannot pass through it. In reversible electro-
poration, the cell membrane is permeabilized to molecules
otherwise deprived of transmembrane transport mechan-
isms. This is a transient phenomenon as after a short time
the membrane reseals and reestablishes its homeostatic
semipermeable properties, allowing ions and other small
molecules to passively cross.
With reversible electroporation, the cell can survive; though
if the molecular transport disruptions to homeostasis are too
great, the cell will die and this process is termed irreversible
electroporation (IRE) and can be used to ablate tissue, partic-
ularly solid tumors. Reversible electroporation has been used in
conjunction with chemotherapeutics, electrochemotherapy
(ECT), and to deliver genes, gene electrotransfer.
At the second World Congress, there were many presenta-
tions highlighting the use of PEF in the medical field. In addi-
tion to traditional reversible electroporation and IRE,
researchers are pushing the envelope and are assessing the
potential application of nanosecond PEF and high-frequency
electroporation for the treatment of cancer.
This special collection contains reports that cover many
aspects of the use of PEF to treat cancer. In the area of IRE,
several breakthrough approaches are reported. The use of high-
frequency IRE (H-FIRE) as a means to enhance the treatment
of intracranial meningiomas is reported (Latouche, 2018 #22).
The collection also includes a report on the first clinical trial
utilizing H-FIRE for prostate cancer (Dong, 2018 #9). Another
interesting approach is the development of a navigation system
combined with treatment planning to allow for application of
IRE through a percutaneous approach. This approach will
allow treatment of deep-seated tumors utilizing a minimally
invasive approach (Fuhrmann, 2018 #30). In another aspect
of IRE, a study on a new electrode design that can be utilized
to treat liver tumors is reported (Ritter, 2018 #36). The collec-
tion contains a related study, a report on combining moderate
heat with nanosecond pulses as a means of effectively treating
squamous cell carcinoma in a preclinical model (Edelblute,
2018 #35).
The collection includes several reports on the use of PEF for
drug delivery also known as ECT. An excellent review of the
use of ECT is included (Probst, 2018 #5). An interesting study
reports on the use of novel needle electrodes for the treatment
of breast cancer (Vera-Tizatl, 2018 #15). There is also a report
utilizing finite element analysis to evaluate the use of in vivo
ECT (Pintar, 2018 #11). A new area related to ECT is the use of
PEF to deliver calcium to treat cancer as opposed to a
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chemotherapeutic agent. The studies reported on the evaluation
of the use of calcium electroporation and the effect on normal
and malignant cells as well as an optimization study on multi-
ple tumor models (Romeo, 2018 #24; Frandsen, 2018 #25).
An important aspect of advancing these technologies is to
better understand the mechanisms that enable the success of
these approaches. This enables a way to better apply the tech-
nologies in a safe and effective manner. One study reports on
the effect of tissue inhomogeneity and how that can influence
the application of PEF (Campana, 2018 #10). One study eval-
uated the use of high-frequency nanosecond pulses and how
that relates to muscle contractions (Mi, 2018 #8). Two papers
in the collection report on membrane permeability and trans-
port through the membrane (Sweeney, 2018 #14; Sweeney,
2018 #31). Another paper demonstrates electrogene transfer
of plasmid DNA in spheroids (Znidar, 2018 #2), while another,
studies vascular effects after targeted gene therapy in combi-
nation with tumor irradiation (Savarin, 2018 #3). These are
important analyses that will enable design of better protocols
to enhance delivery. Included in the collection is an interesting
use of magnetic resonance imaging to map hypoxic levels in
tumors (Sersˇa, 2018 #16).
This special collection contains an excellent overview of the
use of PEF technologies to treat cancer. Manuscripts are pro-
vided by leading experts in the field. Whether you are new to
the field or are already utilizing PEF technologies or just inter-
ested in finding out more about it, this collection will provide
you with some of the latest breakthroughs.
We hope to have you join us in Toulouse, France, for the
third World Congress, September 3-6, 2019 (https://wc2019.
electroporation.net).
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